ML-007

Maplight concludes Phase I trial of schizophrenia and dyskinesia therapy
Clinical Trials Arena
Fri, 08/19/22 - 10:38 am
Maplight Therapeutics
clinical trials
ML-007
schizophrenia
dyskinesia